Form 8-K - Current report:
SEC Accession No. 0001193125-22-216404
Filing Date
2022-08-10
Accepted
2022-08-09 19:22:04
Documents
14
Period of Report
2022-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d388405d8k.htm   iXBRL 8-K 25817
2 EX-99.1 d388405dex991.htm EX-99.1 55968
  Complete submission text file 0001193125-22-216404.txt   253230

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA celu-20220809.xsd EX-101.SCH 4483
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE celu-20220809_def.xml EX-101.DEF 13882
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE celu-20220809_lab.xml EX-101.LAB 23365
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE celu-20220809_pre.xml EX-101.PRE 14844
8 EXTRACTED XBRL INSTANCE DOCUMENT d388405d8k_htm.xml XML 5880
Mailing Address 170 PARK AVE FLORHAM PARK NJ 07932
Business Address 170 PARK AVE FLORHAM PARK NJ 07932 (908) 768-2170
Celularity Inc (Filer) CIK: 0001752828 (see all company filings)

EIN.: 831702591 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38914 | Film No.: 221149994
SIC: 2834 Pharmaceutical Preparations